Dogwood Therapeutics, INC DEF 14A proxy statements

Dogwood Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026, to vote on director elections, auditor ratification, and charter amendments.

Dogwood Therapeutics, Inc. calls a special meeting to approve the conversion of non-voting preferred stock into common stock, significantly diluting existing shareholders, and to expand its equity incentive plan.

Dogwood Therapeutics, Inc. provides a Q4 2025 update, detailing its deep commitment to advancing first-in-class therapeutic treatments for cancer patients suffering from neuropathy.

Dogwood Therapeutics obtained an exclusive, royalty-free global license for Serpin Pharma's SP16, a promising drug for chemotherapy-induced peripheral neuropathy, with its Phase 1b study fully funded by the National Cancer Institute.

Dogwood Therapeutics is holding its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to vote on director elections, ratification of the independent accounting firm, and approval of an amendment to the equity incentive plan.

Virios Therapeutics and Wex Pharmaceuticals have merged to create Dogwood Therapeutics, focusing on clinical development of Halneuron, IMC-1, and IMC-2, with existing Virios stockholders receiving a contingent value right (CVR).

Virios Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 18, 2024, featuring proposals for director elections and ratification of the company's independent accounting firm.

Virios Therapeutics updates shareholders on a special meeting to vote on a reverse stock split, salary cuts, and progress in Long-COVID and Fibromyalgia development programs.